Invectys Inc. is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers based in Paris. Invectys develops…
Invectys Inc. to participate in the 2021 Roth Virtual Healthcare Private Company Forum on June 28th, 2021 Houston, TX, USA, May 4, 2021 (GLOBE NEWSWIRE) –…
Invectys nominates Rosemary Williams, CPA, as Vice-President for Administration and Controller Houston, TX, USA, June 1st, 2021 (GLOBE NEWSWIRE) — Invectys…
Invectys, Inc appoints Biopharma Veteran, Praveen Tyle, PhD as President & CEO Houston, TX, USA, May 4, 2021 (GLOBE NEWSWIRE) – Invectys, Inc., a clinical-stage…
AACR Annual Meeting 2021 April 10th – 15th 2021 Invectys was at the AACR’s Annual Meeting 2021. Although online, the AACR Annual Meeting still carried…
Invectys reports in vivo efficacy of its pan anti-tumor anti-HLA-G CAR-T cells These results open new perspectives in oncology for targeting cancer through HLA-G,…
Invectys publishes positive clinical results for its INVAC-1 Phase I Study in Clinical Cancer Research With an extended Phase I and a new delivery method…
ESMO Immuno-Oncology Congress 2019 December 11th – 14th 2019 Palexpo, Geneva, Switzerland Invectys will be attending the 2019 ESMO Immuno-Oncology Congress. From…
